![Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fmodpathol.2015.98/MediaObjects/41379_2015_Article_BFmodpathol201598_Fig1_HTML.jpg)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study | Modern Pathology
![Mayo Clinic on Twitter: "Doctors recommend regular screening tests to help prevent colon cancer by identifying and removing polyps before they turn into cancer. https://t.co/hCmKHbtPrf #ColorectalCancerChat https://t.co/XkugQZKgYG" / Twitter Mayo Clinic on Twitter: "Doctors recommend regular screening tests to help prevent colon cancer by identifying and removing polyps before they turn into cancer. https://t.co/hCmKHbtPrf #ColorectalCancerChat https://t.co/XkugQZKgYG" / Twitter](https://pbs.twimg.com/media/D1EtSFFXgAIZECQ.jpg)
Mayo Clinic on Twitter: "Doctors recommend regular screening tests to help prevent colon cancer by identifying and removing polyps before they turn into cancer. https://t.co/hCmKHbtPrf #ColorectalCancerChat https://t.co/XkugQZKgYG" / Twitter
![Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9204f226-cb0f-48fd-9a03-3dee48622a2c/gr1_lrg.jpg)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial - The Lancet Oncology
![Illustration of female silhouette with highlighted colon cancer. — medicine, cecum - Stock Photo | #236842328 Illustration of female silhouette with highlighted colon cancer. — medicine, cecum - Stock Photo | #236842328](https://st.focusedcollection.com/13422768/i/1800/focused_236842328-stock-photo-illustration-female-silhouette-highlighted-colon.jpg)